Anders Kronborg, CFO and Acting CEO
Chairman of the Board
Jesper Brandgaard, Executive Chairman
Raj Shah and Jonas Agnblad
Founded in 1908, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 6,000 people, serving 93 million patients in more than 130 countries.
LEO Pharma has a clear strategy and ambition to be a global leader in medical dermatology by expanding its leading branded topical dermatology franchise and developing a deep, innovative pipeline.
As an active minority owner in LEO Pharma and partner to the company’s majority owner the LEO Foundation, Nordic Capital will support LEO Pharma on its journey to strengthening its global leadership in medical dermatology and help accelerate innovation and growth.
EUR 1,300 million
Nordic Capital Fund X (minority shareholding)